PRAMLINTIDE
Also known as
PRAMLINTIDE is catalogued in the Peptides Pub research index, with coverage focused on Metabolic health.
Evidence
Strong human RCT or meta-analysis
Risk band
Well-characterized, minor reported AEs
Research goals
Summary
Pramlintide is a recombinant synthetic analogue of the human pancreatic hormone amylin, used in combination with insulin to treat type 1 and type 2 diabetes [2]. As an administered therapeutic it suppresses glucagon secretion, slows gastric emptying, reduces postprandial glucose, and improves glycemic control while supporting weight loss, and it has been shown to lower hemoglobin A1c, serum fructosamine, and total cholesterol [4]. Important caveats include an increased risk of insulin-induced severe hypoglycemia and gastrointestinal/systemic adverse events such as nausea, anorexia, fatigue, and vomiting, with dosing differing by diabetes type [4]. It has not been linked to clinically apparent liver injury [2], and its peptide nature, short half-life, and high molecular weight make clinically important transfer into breastmilk unlikely [1]. Delivery remains a practical challenge, and co-formulation strategies with insulin are being explored to improve adherence [3].
Sources
- 1. Pramlintide Drugs and Lactation Database (LactMed), 2006.
- 2. Pramlintide LiverTox, 2012.
- 3. Pramlintide an Adjunct to Insulin Therapy: Challenges and Recent Progress in Delivery The Journal of pharmacology and experimental therapeutics, 2024.
- 4. Pramlintide acetate American journal of health-system pharmacy : AJHP, 2005.
For educational purposes only.